These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 36715656)
1. Dose of ibrutinib in Waldenström macroglobulinaemia: Less can be more. Tohidi-Esfahani I; Trotman J Br J Haematol; 2023 Jun; 201(5):807-808. PubMed ID: 36715656 [TBL] [Abstract][Full Text] [Related]
2. Ibrutinib in the management of Waldenstrom macroglobulinemia. Yosef A; Touloukian EZ; Nambudiri VE J Oncol Pharm Pract; 2019 Mar; 25(2):434-441. PubMed ID: 29996737 [TBL] [Abstract][Full Text] [Related]
3. Ibrutinib monotherapy outside of clinical trial setting in Waldenström macroglobulinaemia: practice patterns, toxicities and outcomes. Abeykoon JP; Zanwar S; Ansell SM; Gertz MA; Kumar S; Manske M; Novak AJ; King R; Greipp P; Go R; Inwards D; Muchtar E; Habermann T; Witzig TE; Thompson CA; Dingli D; Lacy MQ; Leung N; Dispenzieri A; Gonsalves W; Warsame R; Kyle RA; Rajkumar V; Parikh SA; Kapoor P Br J Haematol; 2020 Feb; 188(3):394-403. PubMed ID: 31468508 [TBL] [Abstract][Full Text] [Related]
4. First-Generation and Second-Generation Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia. Argyropoulos KV; Palomba ML Hematol Oncol Clin North Am; 2018 Oct; 32(5):853-864. PubMed ID: 30190023 [TBL] [Abstract][Full Text] [Related]
5. An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia. Lim KJC; Tam CS Expert Opin Pharmacother; 2020 Sep; 21(13):1555-1564. PubMed ID: 32603202 [TBL] [Abstract][Full Text] [Related]
6. Zanubrutinib for the treatment of Waldenström Macroglobulinemia. Lim KJC; Tam CS Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772 [No Abstract] [Full Text] [Related]
8. A head-to-head Phase III study comparing zanubrutinib versus ibrutinib in patients with Waldenström macroglobulinemia. Tam CS; LeBlond V; Novotny W; Owen RG; Tedeschi A; Atwal S; Cohen A; Huang J; Buske C Future Oncol; 2018 Sep; 14(22):2229-2237. PubMed ID: 29869556 [TBL] [Abstract][Full Text] [Related]
9. Dose reductions in patients with Waldenström macroglobulinaemia treated with ibrutinib. Sarosiek S; Gustine JN; Flynn CA; Leventoff C; Little M; White T; Meid K; Treon SP; Castillo JJ Br J Haematol; 2023 Jun; 201(5):897-904. PubMed ID: 36626914 [TBL] [Abstract][Full Text] [Related]
10. Ibrutinib for the treatment of Waldenström macroglobulinemia. Chakraborty R; Kapoor P; Ansell SM; Gertz MA Expert Rev Hematol; 2015 Oct; 8(5):569-79. PubMed ID: 26138997 [TBL] [Abstract][Full Text] [Related]
11. Ibrutinib for the treatment of Bing-Neel syndrome, a complication of Waldenström macroglobulinemia: Patient case report. Hartsell L; Janes A; Larck C; Park S; Arnall JR J Oncol Pharm Pract; 2019 Sep; 25(6):1534-1539. PubMed ID: 30760164 [TBL] [Abstract][Full Text] [Related]
13. Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. Ferrero S; Gentile M; Laurenti L; Mauro FR; Martelli M; Sportoletti P; Visco C; Zinzani PL; Tedeschi A; Varettoni M Hematol Oncol; 2022 Aug; 40(3):332-340. PubMed ID: 35212014 [TBL] [Abstract][Full Text] [Related]
14. Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib. Castillo JJ; Abeykoon JP; Gustine JN; Zanwar S; Mein K; Flynn CA; Demos MG; Guerrera ML; Kofides A; Liu X; Munshi M; Tsakmaklis N; King R; Yang G; Hunter ZR; Advani RH; Palomba ML; Ansell SM; Gertz MA; Kapoor P; Treon SP Br J Haematol; 2021 Feb; 192(3):542-550. PubMed ID: 33207010 [TBL] [Abstract][Full Text] [Related]
15. Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia: A review. Moore DC J Oncol Pharm Pract; 2021 Dec; 27(8):1993-1999. PubMed ID: 34558376 [TBL] [Abstract][Full Text] [Related]
16. Zanubrutinib for the treatment of adults with Waldenstrom macroglobulinemia. Sarosiek S; Sermer D; Branagan AR; Treon SP; Castillo JJ Expert Rev Anticancer Ther; 2022 May; 22(5):471-478. PubMed ID: 35404729 [TBL] [Abstract][Full Text] [Related]
17. Resolution of Waldenström Macroglobulinemia-Associated Autoimmune Hemolysis With Ibrutinib. Tripathi A; Steingart R J Oncol Pract; 2016 May; 12(5):490-1. PubMed ID: 27170696 [No Abstract] [Full Text] [Related]
18. Bruton tyrosine kinase inhibitors in the management of Waldenström macroglobulinemia. Castillo JJ; Buske C; Trotman J; Sarosiek S; Treon SP Am J Hematol; 2023 Feb; 98(2):338-347. PubMed ID: 36415104 [TBL] [Abstract][Full Text] [Related]
19. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience. Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303 [TBL] [Abstract][Full Text] [Related]
20. Sudden ventricular fibrillation and death during ibrutinib therapy-A case report. Bernardeschi P; Pirrotta MT; Del Rosso A; Fontanelli G; Milandri C Eur J Haematol; 2019 Oct; 103(4):442-443. PubMed ID: 31287200 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]